Elevance Health Reports Q4 & FY25 Results; Issues Significantly Lower FY26 EPS & Revenue Guidance
summarizeSummary
Elevance Health reported fourth quarter 2025 results that were in line with expectations, showing increased operating revenue and diluted EPS. However, full year 2025 adjusted diluted EPS declined compared to the prior year, and operating cash flow also decreased. The most significant market-moving information is the company's full year 2026 outlook, which projects a substantial decline in both GAAP and adjusted diluted EPS, as well as a low single-digit decline in total operating revenue. Furthermore, the company anticipates significant medical membership attrition, particularly in its Commercial Risk-Based, Medicaid, and Medicare Advantage segments, projecting a loss of over 1.3 million members. This negative guidance, coupled with an increase in the benefit expense ratio reflecting higher medical cost trends, indicates a challenging year ahead for the company.
check_boxKey Events
-
一年2025给计给一年2025给计
Reported full year 2025 operating revenue of $197.6 billion, an increase of 13%, but adjusted diluted EPS declined by 8.3% to $30.29 compared to the prior year.
-
一年2026给计给一年2026给计
Projected full year 2026 adjusted diluted EPS to be at least $25.50, a substantial decrease from the $30.29 reported for full year 2025.
-
一年2026给计给一年2026给计
Forecasted a low single-digit decline in total operating revenue for full year 2026, following a 12.8% increase in 2025.
-
一年2026给计给一年2026给计
Anticipates a decrease in total medical membership to 43.175-43.875 million by year-end 2026, down from 45.232 million in 2025, with notable declines in Commercial Risk-Based, Medicaid, and Medicare Advantage.
auto_awesomeAnalysis
Elevance Health reported fourth quarter 2025 results that were in line with expectations, showing increased operating revenue and diluted EPS. However, full year 2025 adjusted diluted EPS declined compared to the prior year, and operating cash flow also decreased. The most significant market-moving information is the company's full year 2026 outlook, which projects a substantial decline in both GAAP and adjusted diluted EPS, as well as a low single-digit decline in total operating revenue. Furthermore, the company anticipates significant medical membership attrition, particularly in its Commercial Risk-Based, Medicaid, and Medicare Advantage segments, projecting a loss of over 1.3 million members. This negative guidance, coupled with an increase in the benefit expense ratio reflecting higher medical cost trends, indicates a challenging year ahead for the company.
在该文件披露时,ELV的交易价格为$312.33,交易所为NYSE,所属行业为Finance,市值约为$717.7亿。 52周交易区间为$273.71至$458.75。 这份文件被评估为消极市场情绪,重要性评分为8/10。